key: cord-0695375-chcblqw7
authors: Lowry, Kathryn P.; Bissell, Michael; Miglioretti, Diana L.; Kerlikowske, Karla; Alsheik, Nila; Macarol, Tere; Bowles, Erin J.A.; Buist, Diana S.M.; Tosteson, Anna N.A.; Henderson, Louise; Herschorn, Sally D.; Wernli, Karen J.; Weaver, Donald L.; Stout, Natasha K.; Sprague, Brian L.
title: Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic
date: 2021-10-19
journal: Radiology
DOI: 10.1148/radiol.2021211808
sha: 56ee166c914671d9c6786feaac3a34cb07b8d72e
doc_id: 695375
cord_uid: chcblqw7

BACKGROUND: The COVID-19 pandemic reduced mammography utilization, potentially delaying breast cancer diagnoses. PURPOSE: To examine breast biopsy recommendations and breast cancers diagnosed before and during the COVID-19 pandemic by mode of detection (screen-detected versus symptomatic) and women's characteristics. MATERIALS AND METHODS: In this secondary analysis of prospectively collected data, monthly breast biopsy recommendations following mammography and/or ultrasound with subsequent biopsy performed were examined from 66 facilities of the Breast Cancer Surveillance Consortium between January 2019 and September 2020. Monthly and cumulative biopsies recommended and performed, and subsequent cancers diagnosed in the pandemic period (March-September 2020) versus the pre-pandemic period were compared using Wald chi-squared tests. Analyses were stratified by mode of detection and race/ethnicity. RESULTS: From January 2019 to September 2020, 17,728 biopsies were recommended and performed with 6,009 subsequent cancers diagnosed. From March to September 2020, there were substantially fewer breast biopsy recommendations with cancer diagnoses compared to 2019 (1,650 in 2020 versus 2,171 in 2019, or 24% fewer in 2020; p<0.001), predominantly due to fewer screen-detected cancers (722 in 2020 versus 1,169 in 2019, or 38% fewer; p<0.001) versus symptomatic cancers (895 in 2020 versus 965 in 2019, or 7% fewer; p=0.27). Declines in cancer diagnoses were largest in Asian women [67 in 2020 versus 142 in 2019, or 53% fewer; p=0.06)] and Hispanic women [82 in 2020 versus 145 in 2019, or 43% fewer; p=0.13), followed by Black women [210 in 2020 versus 287 in 2019, or 27% fewer; p=0.21], and smallest in non-Hispanic White women [1,128 in 2020 versus 1,357 in 2019, or 17% fewer; p=0.09)]. CONCLUSION: There were substantially fewer breast biopsies with cancer diagnoses during the COVID-19 pandemic from March to September 2020 compared to the same period in 2019, with Asian and Hispanic women experiencing the largest declines followed by Black women. See also the editorial by Heller.

I n p r e s s P20GM103644 also supported the work in this study. Ms. Bowles's effort was supported by the National Cancer Institute (R50CA211115).

The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. INTRODUCTION In spring of 2020, the COVID-19 pandemic led to an unprecedented decline in the use of preventive health care services due to safety concerns for patients, providers, and staff. Some of the greatest reductions were seen in cancer screening services including mammography (1-5). In April 2020, a near-total cessation of screening mammography was observed at facilities both within the United States (US) (4) (5) (6) (7) (8) and internationally (9) (10) (11) . By early summer, women were generally encouraged to return for mammography (12) and monthly screening volumes normalized (6, 13, 14) . However, despite the swift return to pre-pandemic monthly volumes, as of July 2020 year-to-date screening and diagnostic mammography examinations in the Breast Cancer Surveillance Consortium (BCSC) were only 66% and 80% of expected volumes, respectively (6) , indicating a substantial deficit in breast cancer screening accumulated during the early stage of the pandemic. Moreover, these deficits were largest in Hispanic and Asian women (6) , adding to existing evidence that the COVID-19 pandemic has disproportionately impacted minoritized racial and ethnic groups (15) .

Less is known about the downstream impact of these observed delays in breast cancer screening, and it is not yet clear how these delays will ultimately impact breast cancer outcomes. Simulation models have predicted breast cancer screening delays due to the pandemic will lead to 2 487 excess breast cancer deaths in the US over 10 years (0.5% increase) (16) . While the true impact on breast cancer mortality will not be known for many years, intermediate metrics such as cancer diagnosis rates are important indicators that warrant evaluation. One analysis from a large national clinical laboratory database reported a 52% reduction in breast cancer diagnoses in March-April 2020 during the pandemic onset (17) . However, it is not known whether delays in diagnosis resolved following the normalization of breast imaging volumes in early summer 2020.

Pandemic-related declines in breast cancer diagnoses in the United States by mode of detection and woman-level characteristics have not previously been well established in the I n p r e s s literature. In this study, we examine breast biopsy recommendations and breast cancers diagnosed at BCSC facilities before and during the COVID-19 pandemic through September 2020. We specifically examine cancers diagnosed by mode of detection (screening versus diagnostic evaluation), type of cancers detected, and women's characteristics.

Clinical, imaging and pathologic data were prospectively collected by seven breast 

Each registry provided monthly counts of breast biopsy recommendations with biopsy performed in women aged 18 and older between January 2019 and September 2020. Biopsy recommendations were defined as diagnostic mammograms or breast ultrasounds performed with a BI-RADS assessment category of 4 (suspicious) or 5 (highly suggestive of malignancy) (18) . Pathology linkage was used to identify biopsy results within 90 days of the biopsy recommendation and the biopsy outcome (malignant breast carcinoma versus benign). If multiple biopsies were performed within 90 days, the most severe outcome was assigned (invasive carcinoma > ductal carcinoma in situ (DCIS) > benign) as in prior work (19) .

Cancers diagnosed were defined as screen-detected if the woman had a screening mammogram with an abnormal assessment (BI-RADS categories 0, 3, 4, or 5) within the 90 days before diagnostic evaluation, or if the diagnostic examination indication was "additional evaluation of an abnormal screen." Cancers diagnosed were defined as symptomatic if the examination indication was "breast problem" or the woman had no abnormal screening mammogram within the preceding 90 days.

In all analyses, the index month was defined as the month of biopsy recommendation.

Monthly counts of biopsies recommended and cancers diagnosed were pooled across registries, and 2020 volumes were compared to 2019 using Wald chi-squared tests, with P<0.05 considered to be statistically significant. To account for clustering within BCSC registries, we estimated 95% confidence intervals (CIs) using Poisson regression with overdispersion.

Analyses for biopsy recommendations and cancers diagnosed were stratified by age group I n p r e s s (<40, 40-49, 50-59, 60-69, 70+ years) and by race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Asian, >1 race/ethnicity, other race/ethnicity, or unknown). Cancer diagnoses were also stratified by mode of detection (screen-detected vs symptomatic) and cancer type (invasive carcinoma or DCIS). Finally, given the small sample sizes for some race/ethnicity groups, we performed a sensitivity analysis of our results stratified by race/ethnicity using a leave-one-out approach comparing results after removal of each registry, one at a time.

Statistical analyses were performed in SAS statistical software version 9.4 (SAS Institute).

Of 71 facilities across the 7 registries, 66 were included in the analysis (exclusions: 1 facility only performed screening mammography; 4 facilities were unable to provide data for the entire study period). Between January 2019 and September 2020, there were 20,790 biopsy recommendations following mammography and/or ultrasound, with 17,728 biopsies performed (85.5%) and 6,009 cancers diagnosed within 90 days of the recommendation. Most women (66%; n=11,766) were aged 50 or older; 62% (n=11,240) were non-Hispanic White, 11% (n=2,097) non-Hispanic Black, 9% (n=1395) Hispanic, 8% (n=1,252) Asian, 2% (n=303) >1 or other race/ethnicity, and 9% (n=1,441) unknown (Table 1) . (Figure 3 , Table 3 ). Diagnoses of both invasive breast carcinoma and DCIS were lower in 2020 versus 2019 (Table 3) (Table 3) .

Women aged 40 and older had fewer biopsies and cancers diagnosed during March-September 2020 compared to March-September 2019 (p<0.001 for all groups) ( Table 4 ). In women aged <40, 91 cancers were diagnosed from March-September 2020 versus 75 in 2019 [21% higher in 2020, 95% CI -17%, +78%; p=0.32)]. Declines in biopsies and breast cancer diagnoses in the pre-pandemic versus pandemic period varied widely across race/ethnicity groups. The largest declines in biopsies recommended and performed were in Asian women I n p r e s s 17% fewer in 2020 (95%CI -33%, +3%; p=0.09)]. In our sensitivity analysis, these results were generally similar after leaving each registry out, one at a time, for non-Hispanic White women (results ranging from 13-26% fewer biopsies with cancer diagnoses in 2020 versus 2019), Asian women (ranging from 37-58% fewer in 2020) and Hispanic women (ranging from 40-47% fewer in 2020), while differences for Black women varied more widely (ranging from 30% fewer to 10% more than 2020) (Tables E1A and E1B) .

Although the impact of the COVID-19 pandemic on breast cancer mortality will not be known for many years, intermediate outcomes including breast cancer diagnoses can provide important insight into the magnitude of pandemic-related delays in breast cancer care and populations most likely to be impacted. In this analysis of data from 66 facilities in seven BCSC registries, breast cancer diagnoses declined sharply during the initial phase of the COVID-19 pandemic (71% fewer cancer diagnoses in April 2020 compared to 2019) but by June 2020 were similar to 2019. However, as of September 2020, substantially fewer total breast cancers were diagnosed since the start of the COVID-19 pandemic (24% fewer in 2020 than in 2019), predominantly due to reductions in screen-detected cancers (38% fewer). Declines in breast cancer diagnoses in the pandemic versus pre-pandemic period varied substantially by race/ethnicity groups, with the largest differences in Asian women (53% fewer) and Hispanic women (43% fewer), followed by Black women (27% fewer).

Our finding that declines in cancer diagnoses were predominantly due to declines in screen-detected cancers is consistent with prior work (6, 8, 14) showing the pandemic had a larger impact on screening than diagnostic breast imaging. While monthly screening volumes normalized in summer 2020 (6, 13, 14) , imaging volumes above typical volumes would be required to overcome this deficit in cancer diagnoses by rescheduling missed mammography examinations from earlier in the pandemic. One prior analysis of screening mammography I n p r e s s claims data estimated that clearing the queue of delayed screening mammograms would take at best 22 weeks after resumption of normal volumes (corresponding to late fall or early winter of 2020), and that full catch-up might not be attainable at all (8) . Of note, we are not able to discern from our data to what extent the catch-up of cancer diagnoses is hindered by the limited capacity of breast imaging facilities versus other pandemic-related factors impacting access to health care, such as loss of employment/insurance and/or women's concerns about COVID-19 exposure.

In contrast to screen-detected cancers, we found that while symptomatic cancer diagnoses were lower in April and May 2020 compared to 2019, there was a small catch-up period in June and July; as a result, there were no differences in total symptomatic cancer diagnoses for breast imaging evaluations through September 2020. Our findings are consistent with the efforts of breast imaging facilities to prioritize women with symptoms of breast cancer over screening of asymptomatic women during periods of limited capacity (20) and/or may reflect women's greater reluctance to delay evaluation of breast symptoms than a screening examination. A recent study of the Dutch national breast screening program similarly found that pandemic-related shutdowns had a smaller impact on non-screen detected cancer incidence than screen-detected cancer incidence (21). In a prior analysis using breast cancer models from the Cancer Intervention and Surveillance Modeling network, delays in diagnostic evaluation of symptomatic women were more detrimental to long-term outcomes than delays in screening mammography, resulting in excess breast cancer mortality (16) . Thus, it is reassuring that the initial delays in breast cancer diagnoses among symptomatic women have likely largely resolved. Interestingly, we found that symptomatic breast cancer diagnoses decreased in September 2020, with 25% fewer diagnoses than in 2019. However, this may be due to statistical "noise" as this finding did not meet statistical significance and there was no corresponding delay in screen-detected cancers.

We found variation in the magnitude of the differences in breast cancer diagnoses during the pandemic versus pre-pandemic periods across women of different race/ethnicity groups.

Notably, substantially fewer cancers were diagnosed in Asian, Hispanic, and non-Hispanic

Black women compared to non-Hispanic White women. These results are consistent with prior studies which have found racial/ethnic disparities in breast cancer screening and diagnostic imaging use during the pandemic (6, 22, 23) . Greater pandemic-related delays have also been observed among Asian and Hispanic individuals for imaging in general (15) and for individuals residing in communities with high levels of poverty (15, 24) . While it is not possible to definitively identify the factors driving these disparities based on our results, the pandemic has disproportionately impacted minoritized racial/ethnic groups in many ways that could reduce access to breast cancer care. For example, Black, Hispanic, and Asian individuals were more likely to suffer from loss of employment during the pandemic (25) , potentially leading to unstable health insurance coverage. Black and Hispanic populations also experienced disproportionately higher rates of COVID-19 infection, hospitalization, and mortality compared to non-Hispanic White populations (26) , and these risks may have deterred women from seeking non-urgent medical care. It is also possible that breast imaging facilities serving these communities experienced more severe pandemic-related impacts on capacity, further reducing access to mammography. Concerted efforts are needed to elucidate underlying factors that may account for these differences and guide targeted interventions to prevent disparities in breast cancer outcomes for women in minoritized racial/ethnic groups.

Our study has limitations. First, we used aggregated data across multiple geographic regions. This data aggregation process precluded evaluation of local and/or regional COVID-19 burden and social distancing policies that may have further contributed to delays in breast cancer diagnosis. Second, despite our large overall sample size, the small size of race/ethnicity subgroups in our analysis lead to imprecision of estimates. Third, the facilities included in our study were concentrated in the specific geographic regions of our participating registries. Thus, I n p r e s s our findings may not generalize to all regions. Finally, although we included all breast cancers diagnosed within 90 days of breast imaging evaluations performed through September 2020, the full duration and impact of the COVID-19 pandemic is not yet known.

In summary, our study provides important interim estimates of the proportion of women likely to be impacted by delays in breast cancer diagnosis due to pandemic-related disruptions in health care. Our results affirm that delays in breast cancer screening and diagnostic evaluation have resulted in delays in breast cancer diagnoses, with substantially fewer screendetected breast cancers diagnosed from March to September 2020. These differences persisted despite increases in monthly cancer diagnoses, raising concern that delays in screen-detected diagnosis may continue even if imaging facilities are operating at normal capacity. Finally, our findings highlight the ongoing need to improve cancer diagnosis rates among women in minoritized racial/ethnic groups especially, as they experienced greater declines in breast cancer diagnoses during the pandemic. I n p r e s s 148 131 *'All cancers' is greater than screen-detected and symptomatic cancers due to a small number of cases that did not meet the criteria for either mode of detection (e.g., short interval follow-up or diagnostic evaluation not otherwise specified). 

40% fewer in 2020

p=0.08), and Hispanic women

Similarly, breast cancer diagnoses during the pandemic period were largest in Asian women

Characteristics of COVID-19 Community Practice Declines in Noninvasive Diagnostic Imaging Professional Work

Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Imaging Case Volumes

Changes in Health Services Use Among Commercially Insured US Populations During the COVID-19

Cancer Screenings Are Still Lagging

Cancer Screening During the Coronavirus Disease-2019 Pandemic: A Perspective From the National Cancer Institute's PROSPR Consortium

Changes in Mammography Utilization by Women's Characteristics during the First 5 Months of the COVID-19 Pandemic

Impact of COVID-19 on breast imaging case volumes in South Florida: A multicenter study

Disruptions in preventive care: Mammograms during the COVID-19 pandemic. Health services research

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands

The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020

Effects of the COVID-19 pandemic on breast cancer screening in Taiwan

American College of Radiology

Decline and Rebound in Routine Cancer Screening Rates During the COVID-19 Pandemic

Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures

Exacerbation of Inequities in Use of Diagnostic Radiology During the Early Stages of Reopening After COVID-19

Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling

Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease

PubMed Central PMCID: PMCPMC7403918 reported being employed by and owning stock in Quest Diagnostics outside the submitted work

Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer

Society of Breast Imaging. SBI Recommendations for a Thoughtful Return to Caring for Patients

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

Socioeconomic and Racial Inequities in Breast Cancer Screening During the COVID-19 Pandemic in Washington State

COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program

Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors. Breast cancer research and treatment

Inequities in Employment by Race, Ethnicity, and Sector During COVID-19. J Racial Ethn Health Disparities

Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review

34, 5) Non-Hispanic Black -27 (-55, 19) -27 (-51, 7) -27 (-56, 21) -27